Scientifc Program
| Thursday, September 11, 2008 | ||||
| Introductions | ||||
| 8:30 am | Robert Wiltrout | |||
| 8:40 am | John Niederhuber | |||
| 8:50 am | Steven Rosenberg | |||
| Immunotherapies based on T cell transfer or gene modification of lymphocytes Session Chair: Steven Rosenberg |
||||
| 9:00 a.m. | Steven Rosenberg The development of effective cell transfer approaches to the treatment of metastatic cancer |
|||
| 9:30 a.m. | Nicholas Restifo Immunologic principles that guide the development of effective cell transfer therapies |
|||
| 10:00 a.m. | Stanley Riddell Memory makers: Establishing persistent immunity by T cell receptors |
|||
| 10:30 a.m. | -BREAK- | |||
| 10:50 a.m. | Carl June Engineering T cells for adoptive therapy |
|||
| 11:20 a.m. | Malcolm Brenner Redirecting virus specific T lymphocytes towards malignant cells |
|||
| 11:50 a.m. | Philip Greenberg Targeting tumors with T cells: Recognizing antigen is the easy part |
|||
| 12:20 p.m. | Lunch and poster viewing | |||
| 1:45 p.m. | Michel Sadelain Targeting tumors with genetically enhanced lymphocytes |
|||
| 2:15 p.m. | Michel Jensen Genetically modified T cells for cancer immunotherapy |
|||
| 2:45 p.m. | C.H.J. Lamers Immunotherapies based on T cel tyransfer or gene modification of lymphocytes |
|||
| 3:15 p.m. | -BREAK- | |||
| Antibody-based therapies Session Chair: Thomas Waldmann |
||||
| 3:35 p.m. | Thomas Waldmann Systemic radioimmunotherapy of lymphoma with monoclonal antibodies |
|||
| 4:05 p.m. | Ira Pastan Recombinant immunotoxins in the treatment of cancer |
|||
| 4:35 p.m. | Jeffrey Ravetch Engineering antibodies for greater efficacy as anti-cancer agents |
|||
| 5:05 p.m. | Poster Presentations | |||
| Friday, September 12, 2008 | ||||
| Transplantation-based therapies Session Chair: Ronald Gress |
||||
| 8:00 a.m. | Ronald Gress Overview of the role of anti-tumor responses in allogeneic transplantation |
|||
| 8:30 a.m. | Daniel Fowler Th2 cell "infectious" transplant tolerance as a platform for cancer therapy |
|||
| 9:00 a.m. | Bruce Blazar Development and clinical applications of regulatory T cells in recipients of umbilical cord blood transplants |
|||
| 9:30 a.m. | Richard O'Reilly Adoptive T-cell therapy for treatment of residual disease following allogeneic hematopoietic cell transplants |
|||
| 10:00 a.m. | -BREAK- | |||
| Vaccine-based therapies Session Chair: Jeffrey Schlom |
||||
| 10:20 a.m. | Jay Berzofsky Strategies for Cancer Vaccines |
|||
| 10:50 a.m. | Jeffrey Schlom Status of pox virus vaccines in cancer as a monotherapy or combination therapies |
|||
| 11:20 a.m. | Ronald Levy Role of vaccines in the treatment of hematopoietic cancers |
|||
| 11:50 a.m. | Elizabeth Jaffee Vaccines for the treatment of solid cancers |
|||
| 12:20 p.m. | -Lunch- | |||
| Immune modulatory molecules Session Chair: James Yang |
||||
| 1:45 p.m. | James Allison Immunologic checkpoints in cancer therapy |
|||
| 2:15 p.m. | James Yang CTLA-4: Clinical studies |
|||
| 2:35 p.m. | Suzanne Topalian PD-1/PDL-1 |
|||
| 2:55 p.m. | George Pavlakis IL-15/IL-15R |
|||
| 3:15 p.m. | Robert Vonderheide CD40 |
|||
| 3:35 p.m. | Crystal Mackall IL-7 |
|||
| 3:55 p.m. | John Janik IL-12 |
|||
| 4:15 p.m. | John Morris TGF-Beta |
|||
| 4:35 p.m. | -Adjourn- | |||
